Trial Outcomes & Findings for Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL (NCT NCT01994382)

NCT ID: NCT01994382

Last Updated: 2022-04-05

Results Overview

DLT was defined as any of the following toxicities, possibly or probably related to cerdulatinib, and clinically significant (in the judgement of Investigator): -Febrile neutropenia (absolute neutrophil count \<1000/microliter \[μL\] and temperature ≥38.5°Celcius). -Grade 4 neutropenia for \>5 days. -Grade 4 thrombocytopenia with or without bleeding. -Grade 3 thrombocytopenia with bleeding. -Grade 4 anemia, unexplained by underlying disease. -Grade 3 or greater nausea, vomiting, or diarrhea if persistent despite optimal antiemetic or anti-diarrheal therapy. -Grade 3 or greater increase in transaminases lasting \>5 days. -Grade 3 or greater fatigue persisting \>7 days in absence of any other underlying cause. -Any other Grade 3 or greater non-hematologic toxicity (except fatigue as noted above) considered clinically significant by Investigator. -Toxicity of any grade resulting in dose delay of \>7 days. -Toxicity resulting in study drug discontinuation prior to completion of Cycle 1.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

260 participants

Primary outcome timeframe

Baseline up to Day 28 of Cycle 1 (cycle = 21 days or 28 days)

Results posted on

2022-04-05

Participant Flow

This was an open-label study with 2 phases.

Phase 1: dose-escalation portion of study, participants received doses of cerdulatinib at assigned regimen. Phase 2a: participants were enrolled into cohorts based on cancer type and received single agent cerdulatinib except for 1 cohort, participants received cerdulatinib+rituximab. Three participants in Phase 1 rolled over to Phase 2; their data are included in respective arms in both phases. Therefore, the data are included twice in the Totals for Participant Flow \& Baseline Characteristics.

Participant milestones

Participant milestones
Measure	Phase 1: Cerdulatinib 15 Milligrams (mg) Once Daily (QD) Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg Twice Daily (BID) Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 40 mg QD Participants received oral cerdulatinib at 40 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with follicular lymphoma (FL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with marginal zone lymphoma/Waldenström's macroglobulinemia (MZL/WM) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. Participants also received intravenous (IV) injections of rituximab 375 milligrams (mg)/square meter (m\^2) on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aggressive non-Hodgkin lymphoma (aNHL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with peripheral T-cell lymphoma (PTCL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with cutaneous T-cell lymphoma (CTCL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.
Overall Study STARTED	3	6	7	3	3	3	4	6	3	5	42	12	26	6	28	65	41
Overall Study Received at Least 1 Dose of Study Drug	3	6	7	3	3	3	4	6	3	5	42	12	26	6	28	65	41
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	3	6	7	3	3	3	4	6	3	5	42	12	26	6	28	65	41

Reasons for withdrawal

Reasons for withdrawal
Measure	Phase 1: Cerdulatinib 15 Milligrams (mg) Once Daily (QD) Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg Twice Daily (BID) Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 40 mg QD Participants received oral cerdulatinib at 40 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with follicular lymphoma (FL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with marginal zone lymphoma/Waldenström's macroglobulinemia (MZL/WM) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. Participants also received intravenous (IV) injections of rituximab 375 milligrams (mg)/square meter (m\^2) on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aggressive non-Hodgkin lymphoma (aNHL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with peripheral T-cell lymphoma (PTCL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with cutaneous T-cell lymphoma (CTCL) received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.
Overall Study Informed consent withdrawn	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Overall Study Progressive disease	3	4	4	3	2	3	3	6	2	2	13	8	7	3	6	44	28
Overall Study Physician Decision	0	1	0	0	0	0	0	0	0	0	3	1	1	0	1	4	2
Overall Study Death	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	1	0
Overall Study Adverse Event	0	1	2	0	0	0	0	0	0	0	15	2	7	3	17	6	3
Overall Study Other than specified	0	0	0	0	0	0	0	0	0	0	2	0	2	0	0	4	4
Overall Study Withdrawal by Subject	0	0	0	0	0	0	0	0	0	0	6	0	2	0	4	3	0
Overall Study Lost to Follow-up	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Overall Study Participants rolled over into expanded access program (NCT04757259)	0	0	0	0	0	0	0	0	0	0	2	0	7	0	0	3	2
Overall Study Protocol violation/noncompliance	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2
Overall Study Rolled over to Phase 2a	0	0	1	0	0	0	0	0	0	2	0	0	0	0	0	0	0

Baseline Characteristics

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase 1: Cerdulatinib 15 mg QD n=3 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=6 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=7 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=3 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 40 mg QD n=3 Participants Participants received oral cerdulatinib at 40 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=3 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=4 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD n=6 Participants Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD n=3 Participants Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID n=5 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) n=42 Participants Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (MZL/WM Cohort) n=12 Participants Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) n=26 Participants Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) n=6 Participants Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) n=28 Participants Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (PTCL Cohort) n=65 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CTCL Cohort) n=41 Participants Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Total n=263 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	0 Participants n=62 Participants	0 Participants n=95 Participants	0 Participants n=129 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=93 Participants	1 Participants n=4 Participants	3 Participants n=27 Participants	0 Participants n=483 Participants	3 Participants n=36 Participants	2 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=40 Participants	1 Participants n=8 Participants	1 Participants n=62 Participants	23 Participants n=95 Participants	7 Participants n=129 Participants	13 Participants n=36 Participants	2 Participants n=36 Participants	8 Participants n=24 Participants	33 Participants n=135 Participants	21 Participants n=136 Participants	120 Participants n=44 Participants
Age, Categorical >=65 years	2 Participants n=93 Participants	5 Participants n=4 Participants	4 Participants n=27 Participants	3 Participants n=483 Participants	0 Participants n=36 Participants	1 Participants n=10 Participants	4 Participants n=115 Participants	5 Participants n=40 Participants	2 Participants n=8 Participants	4 Participants n=62 Participants	19 Participants n=95 Participants	5 Participants n=129 Participants	13 Participants n=36 Participants	4 Participants n=36 Participants	20 Participants n=24 Participants	32 Participants n=135 Participants	20 Participants n=136 Participants	143 Participants n=44 Participants
Sex: Female, Male Female	0 Participants n=93 Participants	2 Participants n=4 Participants	3 Participants n=27 Participants	2 Participants n=483 Participants	0 Participants n=36 Participants	2 Participants n=10 Participants	1 Participants n=115 Participants	1 Participants n=40 Participants	0 Participants n=8 Participants	2 Participants n=62 Participants	16 Participants n=95 Participants	4 Participants n=129 Participants	9 Participants n=36 Participants	1 Participants n=36 Participants	12 Participants n=24 Participants	24 Participants n=135 Participants	18 Participants n=136 Participants	97 Participants n=44 Participants
Sex: Female, Male Male	3 Participants n=93 Participants	4 Participants n=4 Participants	4 Participants n=27 Participants	1 Participants n=483 Participants	3 Participants n=36 Participants	1 Participants n=10 Participants	3 Participants n=115 Participants	5 Participants n=40 Participants	3 Participants n=8 Participants	3 Participants n=62 Participants	26 Participants n=95 Participants	8 Participants n=129 Participants	17 Participants n=36 Participants	5 Participants n=36 Participants	16 Participants n=24 Participants	41 Participants n=135 Participants	23 Participants n=136 Participants	166 Participants n=44 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	1 Participants n=62 Participants	2 Participants n=95 Participants	1 Participants n=129 Participants	1 Participants n=36 Participants	0 Participants n=36 Participants	1 Participants n=24 Participants	6 Participants n=135 Participants	1 Participants n=136 Participants	13 Participants n=44 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	3 Participants n=93 Participants	6 Participants n=4 Participants	7 Participants n=27 Participants	3 Participants n=483 Participants	3 Participants n=36 Participants	2 Participants n=10 Participants	4 Participants n=115 Participants	6 Participants n=40 Participants	3 Participants n=8 Participants	3 Participants n=62 Participants	37 Participants n=95 Participants	10 Participants n=129 Participants	24 Participants n=36 Participants	5 Participants n=36 Participants	26 Participants n=24 Participants	53 Participants n=135 Participants	37 Participants n=136 Participants	232 Participants n=44 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	1 Participants n=62 Participants	3 Participants n=95 Participants	1 Participants n=129 Participants	1 Participants n=36 Participants	1 Participants n=36 Participants	1 Participants n=24 Participants	6 Participants n=135 Participants	3 Participants n=136 Participants	18 Participants n=44 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	1 Participants n=62 Participants	1 Participants n=95 Participants	0 Participants n=129 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	1 Participants n=136 Participants	3 Participants n=44 Participants
Race (NIH/OMB) Asian	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	0 Participants n=62 Participants	2 Participants n=95 Participants	0 Participants n=129 Participants	1 Participants n=36 Participants	0 Participants n=36 Participants	1 Participants n=24 Participants	2 Participants n=135 Participants	0 Participants n=136 Participants	6 Participants n=44 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	0 Participants n=62 Participants	0 Participants n=95 Participants	0 Participants n=129 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	1 Participants n=136 Participants	1 Participants n=44 Participants
Race (NIH/OMB) Black or African American	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	1 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	0 Participants n=62 Participants	1 Participants n=95 Participants	1 Participants n=129 Participants	2 Participants n=36 Participants	0 Participants n=36 Participants	3 Participants n=24 Participants	10 Participants n=135 Participants	11 Participants n=136 Participants	29 Participants n=44 Participants
Race (NIH/OMB) White	3 Participants n=93 Participants	6 Participants n=4 Participants	7 Participants n=27 Participants	3 Participants n=483 Participants	2 Participants n=36 Participants	3 Participants n=10 Participants	4 Participants n=115 Participants	6 Participants n=40 Participants	3 Participants n=8 Participants	4 Participants n=62 Participants	36 Participants n=95 Participants	11 Participants n=129 Participants	22 Participants n=36 Participants	6 Participants n=36 Participants	23 Participants n=24 Participants	48 Participants n=135 Participants	24 Participants n=136 Participants	211 Participants n=44 Participants
Race (NIH/OMB) More than one race	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	0 Participants n=62 Participants	0 Participants n=95 Participants	0 Participants n=129 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	0 Participants n=62 Participants	2 Participants n=95 Participants	0 Participants n=129 Participants	1 Participants n=36 Participants	0 Participants n=36 Participants	1 Participants n=24 Participants	5 Participants n=135 Participants	4 Participants n=136 Participants	13 Participants n=44 Participants

PRIMARY outcome

Timeframe: Baseline up to Day 28 of Cycle 1 (cycle = 21 days or 28 days)

Population: The Safety Analysis Population included participants who received at least 1 dose of study drug. Only data from participants in Phase 1 cohorts (arms) were applicable and evaluated for this Outcome Measure. Evaluable participants for this Outcome Measure must have received 80% of doses in Cycle 1 or withdrawn from study drug due to drug-related toxicity.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=3 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=3 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=6 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=7 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=3 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=3 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=4 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD n=6 Participants Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD n=3 Participants Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID n=5 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 1: Number of Participants With a Dose Limiting Toxicity (DLT)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline up to End of Treatment (up to last day of Cycle 10 [cycle = 28 days])

Population: The Efficacy Analysis Population included all participants who took at least 1 dose of study drug and had at least 1 post-baseline Investigator response assessment. Only the cohorts (arms) with participants with FL or with PTCL were applicable and evaluated for this Outcome Measure. Here, 'Number of participants analyzed' signifies participants evaluable for this outcome measure.

CR included: -Via a positron emission tomography (PET)/computed tomography (CT) scan, score of 1 (no uptake above background), 2 (uptake of \<mediastinum), or 3 (uptake of \>mediastinum but \<liver) for lymph nodes and extralymphatic sites; no new lesions; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. -Via CT scan, target nodes/nodal masses regressed to \<1.5 centimeters (cm) in longest transverse diameter of a lesion (LDi); no extralymphatic sites of disease; organ enlargement has regressed to normal; and bone marrow was normal by morphology and if indeterminate, immunohistochemistry was negative. PR included: -Via a PET/CT scan, score of 4 (uptake of moderately \>liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with baseline and residual masses of any size. -Via CT scan, \>50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=27 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=24 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=10 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=16 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=10 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=9 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=22 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 2a: Number of Participants Achieving Overall Response Rate (Partial Response [PR] Plus Complete Response [CR]) as Assessed by the Investigator	14 Participants	12 Participants	6 Participants	15 Participants	5 Participants	0 Participants	7 Participants	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline up to End of Treatment (up to last day of Cycle 10 [cycle = 21 days or 28 days])

CR included: -Via a PET/CT scan, score of 1 (no uptake above background), 2 (uptake of \<mediastinum), or 3 (uptake of \>mediastinum but \<liver) for lymph nodes and extralymphatic sites; no new lesions; and no evidence of FDG-avid disease in bone marrow. -Via CT scan, target nodes/nodal masses regressed to \<1.5 cm in LDi; no extralymphatic sites of disease; organ enlargement has regressed to normal; and bone marrow was normal by morphology and if indeterminate, immunohistochemistry was negative. PR included: -Via a PET/CT scan, a score of 4 (uptake of moderately \>liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with baseline and residual masses of any size. -Via CT scan, \>50% decrease in the sum of the product of perpendicular diameters for multiple lesion of up to 6 target measurable nodes and extranodal sites.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=3 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=3 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=6 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=7 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=3 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=3 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=4 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD n=6 Participants Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD n=3 Participants Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID n=5 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 1: Number of Participants Achieving Overall Response Rate (Partial Response [PR] Plus Complete Response [CR]) as Assessed by the Investigator	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline up to End of Treatment (up to last day of Cycle 10 [cycle = 21 days or 28 days])

Clinical benefit was defined as achieving stable disease (SD) or better, as assessed by the Investigator. SD included: -Via a PET/CT scan, a score of 4 (uptake of moderately \>liver) or 5 (uptake markedly higher than liver and/or new lesions) with no significant change in FDG uptake from baseline at interim or end of treatment; no new lesions; and no change from baseline in bone marrow. -Via CT scan, \<50% decrease from baseline in sum of products of the greatest perpendicular diameters (SPD) of up to 6 dominant, measurable nodes and extranodal sites; no increase consistent with progression in nonmeasured lesions or organ enlargement; and no new lesions.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=3 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=3 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=6 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=7 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=3 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=3 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=4 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD n=6 Participants Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD n=3 Participants Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID n=5 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 1: Number of Participants Achieving Clinical Benefit	1 Participants	2 Participants	4 Participants	4 Participants	1 Participants	0 Participants	2 Participants	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days])

Population: The Safety Analysis Population included participants who received at least 1 dose of study drug.

An AE is any untoward medical occurrence, which may or may not have a causal relationship to the study drug, including: unfavorable and unintended sign, symptom, or disease temporally associated with the use of the study drug; any newly occurring event or exacerbation of previous condition (for example, increase in severity or frequency) since the administration of study drug; recurrence of an intermittent medical condition not present at baseline; any deterioration in a laboratory value or other clinical test that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug; and AEs related to a study intervention. An SAE is an AE that is fatal, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or a congenital anomaly/birth defect.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=3 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=3 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=6 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=7 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=3 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=3 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=4 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD n=6 Participants Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD n=3 Participants Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID n=5 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) n=42 Participants Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) n=12 Participants Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) n=26 Participants Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) n=6 Participants Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) n=28 Participants Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) n=65 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) n=41 Participants Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 1 and Phase 2: Number of Participants With an Adverse Event (AE) or a Serious Adverse Event (SAE) AE	3 Participants	3 Participants	6 Participants	7 Participants	3 Participants	3 Participants	4 Participants	6 Participants	3 Participants	5 Participants	42 Participants	12 Participants	26 Participants	6 Participants	28 Participants	65 Participants	41 Participants
Phase 1 and Phase 2: Number of Participants With an Adverse Event (AE) or a Serious Adverse Event (SAE) SAE	1 Participants	0 Participants	2 Participants	4 Participants	0 Participants	0 Participants	2 Participants	2 Participants	2 Participants	3 Participants	22 Participants	2 Participants	7 Participants	3 Participants	17 Participants	42 Participants	21 Participants

SECONDARY outcome

Timeframe: Cycle (C)1 Day (D)1: predose (0), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, and 72 hours postdose (except 15mg QD); C1D1: 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours postdose (15mg QD); C2D1: 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours postdose (all doses)

Population: The Pharmacokinetic Analysis Population consisted of all participants who received the requisite treatments and have data at the required timepoints. Only data from participants in Phase 1 cohorts (arms) were applicable and evaluated for this Outcome Measure. Here, 'Number of participants analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable at specified timepoints.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=3 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=3 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=6 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=7 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=3 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=3 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=4 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD n=5 Participants Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD n=3 Participants Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID n=5 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 1: Area Under the Plasma Concentration-Time Curve From 0 to 12 Hours (AUC0-12) of Cerdulatinib Day 1 of Cycle 1	2064 hoursnanograms/milliliter (hng/mL) Standard Deviation 666.52	709.6 hoursnanograms/milliliter (hng/mL) Standard Deviation 37.823	1040 hoursnanograms/milliliter (hng/mL) Standard Deviation 347.34	1826 hoursnanograms/milliliter (hng/mL) Standard Deviation 713.67	601.4 hoursnanograms/milliliter (hng/mL) Standard Deviation 118.04	674.5 hoursnanograms/milliliter (hng/mL) Standard Deviation 113.34	2465 hoursnanograms/milliliter (hng/mL) Standard Deviation 305.70	2719 hoursnanograms/milliliter (hng/mL) Standard Deviation 1208.2	2758 hoursnanograms/milliliter (hng/mL) Standard Deviation 969.37	1335 hoursnanograms/milliliter (hng/mL) Standard Deviation 530.56	—	—	—	—	—	—	—
Phase 1: Area Under the Plasma Concentration-Time Curve From 0 to 12 Hours (AUC0-12) of Cerdulatinib Day 1 of Cycle 2	6313 hoursnanograms/milliliter (hng/mL) Standard Deviation 166.81	1321 hoursnanograms/milliliter (hng/mL) Standard Deviation 140.21	1900 hoursnanograms/milliliter (hng/mL) Standard Deviation 918.79	6804 hoursnanograms/milliliter (hng/mL) Standard Deviation 3065.6	2129 hoursnanograms/milliliter (hng/mL) Standard Deviation 533.14	2779 hoursnanograms/milliliter (hng/mL) Standard Deviation 458.94	5871 hoursnanograms/milliliter (hng/mL) Standard Deviation 3685.1	6215 hoursnanograms/milliliter (hng/mL) Standard Deviation 249.64	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline up to End of Treatment (up to last day of Cycle 10 [cycle = 28 days])

PFS=(first documentation of disease progression \[DP\] or death \[whichever occurred first\]-study drug first dose date+1)/30.4375 in months. PFS right censored for 1 of these conditions: 1) no baseline disease assessments; 2) starting new anticancer therapy before documented DP/death; 3) DP/death immediately after \>6 months since last disease assessment (or \>12 months if after last cycle); \& alive without documented DP. 95% confidence interval estimated using Brookmeyer method. DP included: -Via a PET/CT scan, score of 4 (uptake of moderately \>liver) or 5 (uptake markedly higher than liver and/or new lesions) with uptake increase in intensity, new FDG-avid foci, \& no nonmeasured lesions. -Via CT, abnormal individual node/lesion with significant LDi or shortest axis perpendicular to LDi increase; prior splenomegaly, \>50% splenic length increase; if no prior splenomegaly, ≥2 cm splenic length increase; new or recurrent splenomegaly; new/clear progression of preexisting nonmeasured lesions.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=27 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=24 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=10 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=16 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=10 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=9 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=22 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 2a: Median Time to Progression-Free Survival (PFS)	4.57 months Interval 1.71 to 9.99	12.68 months Interval 4.53 to NA=not applicable. Due to several participants who were censored (see conditions detailed above) the upper limit could not be estimated.	3.61 months Interval 1.28 to Due to several participants who were censored (see conditions detailed above) the upper limit could not be estimated.	18.33 months Interval 10.74 to Due to several participants who were censored (see conditions detailed above) the upper limit could not be estimated.	NA months Interval 3.58 to Due to several participants who were censored (see conditions detailed above) the median and the upper limit could not be estimated.	1.18 months Interval 0.26 to 3.58	3.45 months Interval 2.07 to 5.62	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline up to End of Treatment (up to last day of Cycle 10 [cycle = 28 days])

Clinical benefit was defined as achieving SD or better, as assessed by the Investigator. SD included: -Via a PET/CT scan, a score of 4 (uptake of moderately \>liver) or 5 (uptake markedly higher than liver and/or new lesions) with no significant change in FDG uptake from baseline at interim or end of treatment; no new lesions; and no change from baseline in bone marrow. -Via CT scan, \<50% decrease from baseline in sum of products of the greatest perpendicular diameters (SPD) of up to 6 dominant, measurable nodes and extranodal sites; no increase consistent with progression in nonmeasured lesions or organ enlargement; and no new lesions.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=27 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=24 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=10 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=16 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=10 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=9 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=22 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 2a: Number of Participants Achieving Clinical Benefit	17 Participants	19 Participants	8 Participants	16 Participants	10 Participants	2 Participants	16 Participants	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline up to End of Treatment (up to last day of Cycle 10 [cycle = 28 days])

DMR was defined as achieving a ≥50% decrease from baseline in the SPD of the target nodal and extranodal lesions. SPD at a visit was considered missing if any target lesion was not evaluated.

Outcome measures

Outcome measures
Measure	Phase 2a: Cerdulatinib (PTCL Cohort) With AITL/TFH n=27 Participants Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. This cohort included participants with cancer type of PTCL angioimmunoblastic T-cell lymphoma (AITCL/AITL) and PTCL with T-follicular helper phenotype (TFH).	Phase 1: Cerdulatinib 15 mg QD n=24 Participants Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=10 Participants Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=16 Participants Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=10 Participants Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=9 Participants Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=22 Participants Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (MZL/WM Cohort) Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (PTCL Cohort) Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.	Phase 2a: Cerdulatinib (CTCL Cohort) Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable, at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
Phase 2a: Number of Participants Achieving Dominant Mass Response (DMR)	15 Participants	14 Participants	5 Participants	14 Participants	7 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—	—	—	—

Deaths: 0 deaths

Phase 2a: Cerdulatinib (PTCL Cohort)

Serious events: 42 serious events

Other events: 65 other events

Deaths: 1 deaths

Phase 2a: Cerdulatinib (CTCL Cohort)

Serious events: 21 serious events

Other events: 41 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Phase 1: Cerdulatinib 15 mg QD n=3 participants at risk Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=6 participants at risk Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=7 participants at risk Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=3 participants at risk Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 40 mg QD n=3 participants at risk Participants received oral cerdulatinib at 40 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=3 participants at risk Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=4 participants at risk Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD n=6 participants at risk Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD n=3 participants at risk Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID n=5 participants at risk Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) n=42 participants at risk Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (MZL/WM Cohort) n=12 participants at risk Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) n=26 participants at risk Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) n=6 participants at risk Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) n=28 participants at risk Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (PTCL Cohort) n=65 participants at risk Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CTCL Cohort) n=41 participants at risk Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) T-cell lymphoma	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Non-cardiac chest pain	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Influenza	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Diarrhoea	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.8% 2/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.6% 3/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Diverticulum	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Haematochezia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Large intestine perforation	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Nausea	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Pancreatitis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.8% 2/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Pneumocystis jirovecii pneumonia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Bronchitis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Hepatic infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Lung infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Pneumonia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.2% 5/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.6% 3/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Anaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Autoimmune haemolytic anaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Pancytopenia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Disease progression	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Pyrexia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 5/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic lymphocytic leukaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-Hodgkin lymphoma	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Vascular disorders Hypotension	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Cardiac disorders Acute myocardial infarction	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Psychiatric disorders Confusional state	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Sepsis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.2% 6/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Nocardiosis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Bacteraemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Skin infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Upper respiratory tract infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Cellulitis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Clostridium difficile infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Epstein-Barr virus infection reactivation	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Pneumonia bacterial	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Septic shock	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Staphylococcal bacteraemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Urinary tract infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Brain abscess	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Bronchopulmonary aspergillosis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Corynebacterium sepsis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Cytomegalovirus gastritis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Cytomegalovirus viraemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Device related infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Escherichia bacteraemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Gastroenteritis viral	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Herpes zoster	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Localised infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Neutropenic sepsis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Pneumonia fungal	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Pseudomonal sepsis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Pyelonephritis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Scedosporium infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Soft tissue infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Staphylococcal infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Staphylococcal sepsis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Streptococcal sepsis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations West Nile viral infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Wound infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Vomiting	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Colitis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Dysphagia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Fistula of small intestine	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Uvulitis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 13/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Diffuse large B-cell lymphoma	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma metastatic	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anal squamous cell carcinoma	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal adenocarcinoma	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Death	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Mucosal inflammation	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Multiple organ dysfunction syndrome	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Sudden death	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Swelling face	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Systemic inflammatory response syndrome	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Methaemoglobinaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Haemolysis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Lymph node pain	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.8% 2/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Tumour lysis syndrome	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Gout	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Vascular disorders Embolism	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Vascular disorders Hypertension	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Vascular disorders Orthostatic hypotension	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Cardiac disorders Atrial fibrillation	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Cardiac disorders Acute coronary syndrome	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Cardiac disorders Acute left ventricular failure	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Cardiac disorders Cardiac arrest	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Cardiac disorders Cardiomyopathy	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Cardiac disorders Tachycardia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Syncope	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Acute motor axonal neuropathy	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Cerebral haemorrhage	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Cerebrovascular accident	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Dysarthria	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Transient ischaemic attack	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Renal and urinary disorders Acute kidney injury	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Renal and urinary disorders Haematuria	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications Accidental overdose	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications Toxicity to various agents	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications Wrist fracture	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Platelet count decreased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Amylase increased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Lymphocyte count increased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Neutrophil count decreased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Immune system disorders Cytokine release syndrome	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Immune system disorders Graft versus host disease	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Skin and subcutaneous tissue disorders Drug reaction with eosinophilia and systemic symptoms	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Eye disorders Vision blurred	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Gastritis	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) B-cell lymphoma	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.

Other adverse events

Other adverse events
Measure	Phase 1: Cerdulatinib 15 mg QD n=3 participants at risk Participants received oral cerdulatinib at 15 mg QD starting on Day 1 in 21-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 30 mg QD n=6 participants at risk Participants received oral cerdulatinib at 30 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg QD n=7 participants at risk Participants received oral cerdulatinib at 45 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 15 mg BID n=3 participants at risk Participants received oral cerdulatinib at 15 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 40 mg QD n=3 participants at risk Participants received oral cerdulatinib at 40 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 20 mg BID n=3 participants at risk Participants received oral cerdulatinib at 20 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 50 mg QD n=4 participants at risk Participants received oral cerdulatinib at 50 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 65 mg QD n=6 participants at risk Participants received oral cerdulatinib at 65 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 100 mg QD n=3 participants at risk Participants received oral cerdulatinib at 100 mg on Day 1 and then QD starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 1: Cerdulatinib 45 mg BID n=5 participants at risk Participants received oral cerdulatinib at 45 mg on Day 1 and then BID starting on Day 4 in 28-day cycles for up to 10 cycles.	Phase 2a: Cerdulatinib (FL Cohort) n=42 participants at risk Participants with FL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (MZL/WM Cohort) n=12 participants at risk Participants with MZL/WM received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib Plus Rituximab (FL Cohort) n=26 participants at risk Participants with FL received oral cerdulatinib at starting doses of 30 or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable. Participants also received IV injections of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.	Phase 2a: Cerdulatinib (aNHL Cohort) n=6 participants at risk Participants with aNHL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CLL/SLL Cohort) n=28 participants at risk Participants with CLL/SLL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (PTCL Cohort) n=65 participants at risk Participants with PTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.	Phase 2a: Cerdulatinib (CTCL Cohort) n=41 participants at risk Participants with CTCL received oral cerdulatinib at starting doses of 35 or 30 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib could have been reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID, when applicable.
Respiratory, thoracic and mediastinal disorders Nasal Congestion	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 4/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Lipase Increased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 14/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 3/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	38.5% 10/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 8/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	29.2% 19/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	58.5% 24/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Amylase Increased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	31.0% 13/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	26.9% 7/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	21.4% 6/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	43.1% 28/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	51.2% 21/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Aspartate Aminotransferase Increased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 4/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 5/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	17.1% 7/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Alanine Aminotransferase Increased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 10/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.2% 5/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.8% 2/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 5/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Diarrhoea	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	42.9% 3/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 2/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 4/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	100.0% 3/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	100.0% 5/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	54.8% 23/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	41.7% 5/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	80.8% 21/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	71.4% 20/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	41.5% 27/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	48.8% 20/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Nausea	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	42.9% 3/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	40.0% 2/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	54.8% 23/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 6/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 13/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 3/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 14/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	32.3% 21/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	41.5% 17/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Abdominal Pain	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 2/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 3/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	31.0% 13/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	26.9% 7/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	21.4% 6/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	24.6% 16/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Vomiting	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 2/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	23.8% 10/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	30.8% 8/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.6% 6/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Constipation	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	21.4% 9/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	23.1% 6/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 3/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	21.4% 6/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.2% 6/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.2% 5/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Abdominal Distension	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 2/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.5% 4/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.5% 3/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Fatigue	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	85.7% 6/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 2/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	83.3% 5/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	60.0% 3/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 21/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	58.3% 7/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	57.7% 15/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	57.1% 16/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	27.7% 18/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	34.1% 14/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Pyrexia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	57.1% 4/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 12/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.2% 5/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	21.4% 6/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.3% 8/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.8% 4/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Pain	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Decreased Appetite	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	42.9% 3/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 7/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.2% 5/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	39.3% 11/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.3% 8/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Hyperkalaemia	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Cough	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	42.9% 3/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	66.7% 2/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 7/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 4/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	32.1% 9/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.2% 6/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.6% 6/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 2/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 2/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	21.4% 9/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 4/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	17.9% 5/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.3% 8/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	40.0% 2/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 7/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.8% 7/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders Sinus Congestion	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Weight Decreased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	40.0% 2/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.8% 2/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.2% 5/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	32.1% 9/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Neutrophil Count Decreased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.9% 5/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.7% 3/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 10/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Anaemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 2/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	50.0% 2/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.5% 4/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 4/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	23.1% 6/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	32.1% 9/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	32.3% 21/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	29.3% 12/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	21.4% 9/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	30.8% 8/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 13/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.6% 6/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 2/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.7% 3/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Headache	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 2/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	26.2% 11/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 4/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 7/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	18.5% 12/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Skin and subcutaneous tissue disorders Night Sweats	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.9% 5/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 1/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	26.2% 11/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.3% 8/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.6% 6/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders Back Pain	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 7/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.5% 3/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 1/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Upper Respiratory Tract Infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 6/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.5% 3/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.8% 7/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Psychiatric disorders Insomnia	33.3% 1/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 1/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.7% 3/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Gastrooesophageal Reflux Disease	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.0% 8/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.2% 5/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.3% 8/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Dyspepsia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 7/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 4/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.7% 3/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Gastrointestinal disorders Flatulence	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.7% 3/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Oedema Peripheral	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 7/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.7% 3/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.8% 4/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Chills	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.5% 4/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 3/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.5% 3/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	1.5% 1/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
General disorders Asthenia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 6/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.8% 1/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.8% 7/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Blood Creatinine Increased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.8% 4/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Investigations Blood Lactate Dehydrogenase Increased	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.5% 3/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	17.1% 7/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Paraesthesia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Skin and subcutaneous tissue disorders Rash Maculo-Papular	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.5% 3/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 2/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.6% 3/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.8% 4/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 5/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.8% 4/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.9% 5/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.5% 3/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.6% 3/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	2.4% 1/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders Pain In Extremity	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.5% 4/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	10.7% 3/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.6% 3/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.2% 5/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Dysgeusia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.9% 5/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 4/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	25.0% 7/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	20.0% 13/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.5% 8/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Nervous system disorders Dizziness	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.0% 8/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 2/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	19.2% 5/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	28.6% 8/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.2% 6/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications Fall	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.1% 3/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	9.8% 4/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Urinary Tract Infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	11.9% 5/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	15.4% 4/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.6% 3/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.2% 5/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Infections and infestations Skin Infection	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.6% 1/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	6.2% 4/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	12.2% 5/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders Hypophosphatemia	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.8% 2/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.7% 2/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	33.3% 2/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	3.1% 2/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.9% 2/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.
Vascular disorders Hypertension	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/7 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/4 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/3 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	0.00% 0/5 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	23.8% 10/42 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	8.3% 1/12 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	30.8% 8/26 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	16.7% 1/6 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	14.3% 4/28 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	4.6% 3/65 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.	7.3% 3/41 • Baseline up to End of Study (up to 30 days after last dose in Cycle 10 [cycle = up to 28 days]) The Safety Analysis Population included participants who received at least 1 dose of study drug.

Additional Information

Alexion Pharmaceuticals, Inc.

Phone: +1.855.752.2356

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place